Familial hypercholesterolaemia
KEYWORDS: people, diagnosis, quality, statement, data, treatment, testing, clinical, children, specialist, hypercholesterolaemia, familial hypercholesterolaemia, clinical diagnosis, familial, source

10 years. Commissioners ensure that they commission services in which specialists with expertise in FH assess children with FH for lipid-modifying drug treatment, in a child-focused setting, by the age of 10 years. Children with FH have an assessment for possible drug treatment to reduce the low-density cholesterol (bad cholesterol) in their blood by a specialist in a children's department, by the age of 10 years. Source guidance Familial hypercholesterolaemia: identification and management. NICE guideline CG71 (2008, updated 2019), recommendation 1.3.1.20 Definitions of terms used in this quality statement Familial hypercholesterolaemia (FH) FH relates to heterozygous FH only. Assessment for lipid-modifying drug treatment The decision to offer or defer lipid-modifying drug treatment for a child or young person should take into account their age, age at onset of coronary heart disease within the family and the presence of other cardiovascular risk factors, including their LDL-C concentration. [Adapted from NICE's guideline on familial hypercholesterolaemia, recommendation 1.3.1.18] Specialist with expertise in FH in children and young people A healthcare professional with expertise in FH in children and young people who has access to the wider skills of a multidisciplinary team. This team should include a dietitian, cardiologist and paediatrician, and a clinical
